159 results
8-K
EX-99.2
INVA
Innoviva Inc
10 Sep 13
Other Events
12:00am
: ELLIPTA™ use assessment and ease of use assessment (Studies DB2114417, DB2114418)
ELLIPTA™ use and ease of use were assessed in the first treatment … in the patient information leaflet. Placebo inhalers were used for demonstration in the training assessment.
In the study protocols the correct use of the ELLIPTA
8-K
INVA
Innoviva Inc
24 Jun 13
Other Events
12:00am
& World Allergy Organization World Allergy & Asthma Congress 2013, Milan, Italy, GlaxoSmithKline plc (“GSK”) presented a poster on qualitative assessment …
Exhibit 99.1
Qualitative assessment of a two-strip dry powder inhaler (ELLIPTA™) for COPD and asthma
SIGNATURE
Pursuant to the requirements
8-K
INVA
Innoviva Inc
4 Sep 12
Regulation FD Disclosure
12:00am
(VI) in patients with COPD: low-mid dose assessment
Exhibit 99.2
A dual-acting muscarinic antagonist, beta 2-agonist (MABA) molecule (GSK961081 … furoate (FF)/vilanterol (VI) in patients with COPD: low-mid dose assessment
Exhibit 99.2
A dual-acting muscarinic antagonist, beta 2-agonist (MABA) molecule (GSK961081) improves lung function in COPD: A randomised trial
8-K
EX-99.3
INVA
Innoviva Inc
9 Sep 13
Other Events
12:00am
recorded at the screening visit
FEV1, forced expiratory volume in one second
Inhaler user assessment
· Trial investigators assessed patients’ competence … (%)
Inhaler use assessment (Table 4)
· 95% of patients used the ELLIPTA DPI correctly as adjudicated by the investigator after a single demonstration
8-K
EX-99
INVA
Innoviva Inc
19 Sep 13
Regulation FD Disclosure
12:00am
the fourth quarter of 2013.
As part of its assessment, the EMA reviewed results of 11 clinical studies in 7,851 patients with COPD and 16 studies … development program a total of 7,034 patients were included in an integrated assessment of adverse reactions. In the COPD clinical development
8-K
mbro5w8e
4 Sep 12
Other Events
12:00am
8-K
EX-99.1
arrerp79jqbee aptzh
15 Sep 17
Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD
12:00am
8-K
EX-99.3
x9qz6tgl
4 Sep 12
Other Events
12:00am
S-3ASR
EX-23.1
21n22uhn89t0j
15 Jan 08
Automatic shelf registration
12:00am
CORRESP
gvpf5k
23 Sep 10
Correspondence with SEC
12:00am
8-K
iy3hke2
19 Feb 13
Other Events
12:00am
8-K
EX-99.1
2x2m8wr354axsy1k9b
19 Jun 12
Other Events
12:00am
8-K
EX-99.14
g4a3 c64omcnz0w6gvi
4 Sep 12
Other Events
12:00am
8-K
EX-99.13
cbitj
4 Sep 12
Other Events
12:00am
8-K
EX-99
8f4z0q3
19 Feb 13
Other Events
12:00am
8-K
EX-99.11
3eibft
4 Sep 12
Other Events
12:00am
8-K
EX-10.3
30jm4p y321um
5 Jun 14
Theravance, Inc. and Theravance Biopharma, Inc. Announce
12:00am